PDCD1 and hepatocellular carcinoma: Similarly, the anti-PD-1 antibody sintilimab combined with a bevacizumab biosimilar (IBI305) has been reported to improve OS in Chinese patients with advanced-stage hepatitis B virus (HBV)-associated HCC relative to sorafenib [134].